Guideline No. 409: Intrauterine Fetal Diagnostic Testing in Women with Chronic Viral Infections
R Douglas Wilson,R. Douglas Wilson
DOI: https://doi.org/10.1016/j.jogc.2020.09.007
2020-12-01
Journal of Obstetrics and Gynaecology Canada
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objective</h3><p>This revised guideline provides updated information for the care of women with chronic viral infections who require intrauterine fetal diagnostic testing.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Target Population</h3><p>Women with chronic viral infections who are pregnant or planning a pregnancy.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Options</h3><p>Non-invasive screening tests for diagnosis: maternal serum placental analytes with or without nuchal translucency, sonography, maternal serum cell-free placental DNA; and intrauterine fetal diagnostic testing: amniocentesis, chorionic villus sampling, cordocentesis.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Outcomes</h3><p>The recommendations in this guideline have the potential to decrease or eliminate morbidity and mortality in women with chronic viral infections and their infants, which is associated with significant health and economic outcomes.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Evidence</h3><p>Published literature was retrieved through searches of PubMed, guidelines of national societies (Society of Obstetricians and Gynaecologists of Canada, American College of Obstetricians and Gynecologists, Society for Maternal-Fetal Medicine, other international societies), and the Cochrane Library using appropriate controlled vocabulary (amniocentesis, chorionic villus sampling, cordocentesis, procedure pregnancy loss risk, viral vertical transmission, fetal and neonatal infection) and keywords (maternal infection or exposure, hepatitis B, hepatitis C, human immunodeficiency virus). Results were restricted to systematic reviews, randomized controlled trials or controlled clinical trials (if available), and observational case-control studies or case series from 2012 to 2019 published in English or French. Studies from 1966 to 2002 were previously reviewed in the SOGC guideline <em>No. 123: Amniocentesis and Women with Hepatitis B, Hepatitis C, or Human Immunodeficiency Virus</em>, and those from 2002 to 2012 were previously reviewed in the SOGC guideline <em>No. 309: Prenatal Invasive Procedures in Women With Hepatitis B, Hepatitis C, and/or Human Immunodeficiency Virus Infections</em>. Updated literature searches were completed regularly through August 2019 and were incorporated into this guideline.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Validation Methods</h3><p>The authors rated the quality of evidence and strength of recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. See online Appendix A (<a class="workspace-trigger" href="#tbl0002">Tables A1</a> for definitions and <a class="workspace-trigger" href="#tbl0003">A2</a> for interpretations of strong and weak recommendations).</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Intended Audience</h3><p>The intended users are maternity care providers and women with chronic viral infections. This guideline provides information to educate and counsel these women, and to offer them reproductive options.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">RECOMMENDATIONS (GRADE ratings in parentheses)</h3><dl class="list"><dt class="list-label">1</dt><dd class="list-description"><p>For women with a chronic infection with hepatitis B, hepatitis C, and/or human immunodeficiency virus (HIV), the use of non-invasive methods of fetal aneuploidy risk assessment is recommended, using screening tests with high sensitivity and low false-positive rates (maternal serum placental analytes with or without nuchal translucency, detailed sonography [dating crown-rump length, first- and second-trimester anatomic] and maternal serum cell-free placental DNA as first- or second-tier screening test) (<em>strong, moderate</em>).</p></dd><dt class="list-label">2</dt><dd class="list-description"><p>When counselling pregnant women with a chronic infection that can pose a risk of perinatal morbidity regarding intrauterine fetal diagnostic genetic and/or infectious testing:</p><dl class="list"><dt class="list-label">•</dt><dd class="list-description"><p>The pregnancy loss rate (spontaneous loss rate and rate due to the procedure) discussed should be based on the gestational age at the time of the procedure (<em>strong, high</em>).</p></dd><dt class="list-label">•</dt><dd class="list-description"><p>The first trimester (when chorionic villus sampling is performed) has an estimated spontaneous pregnancy loss rate of 1.40% (based on a population cohort of maternal age >36 years with normal first-trimester sonographic screening); the second trimester (when amniocentesis is performed) has an estimated spontaneous pregnancy loss rate of 0.65% (based on a population cohort of maternal age >36 years with normal second-trimester sonographic screening) (<em>strong, high</em>).</p></dd><dt class="list- <p>-Abstract Truncated-</p>
English Else